Clinical Effect of Phenytoin Mucoadhesive Paste on Wound Healing After Oral Biopsy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2012 by Shahid Beheshti Medical University.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
somayeh alirezaei, Shaheed Beheshti Medical University Identifier:
First received: September 3, 2012
Last updated: October 1, 2012
Last verified: October 2012
several studies have investigated healing effect of phenytoin.In this study we investigate healing effect of phenytoin mucoadhesive paste comparing to the usual mucoadhesive paste after oral biopsy.

Condition Intervention Phase
Wound Healing
Drug: Phenytoin paste
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Phase 1 Study of Phenytoin Mucoadhesive Paste for Wound Healing After Oral Biopsy

Resource links provided by NLM:

Further study details as provided by Shahid Beheshti Medical University:

Primary Outcome Measures:
  • healing biopsy wound [ Time Frame: 7 days ] [ Designated as safety issue: No ]
    patient recieves phenytoin mucoadhesive paste after oral biopsy and the diameter of inflammatory halo is determined in 1,3,5and the 7th days.pain measurment is also assesed by VAS score

Estimated Enrollment: 40
Study Start Date: October 2012
Estimated Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: phenytoin paste
this group receives phenytoin paste after oral biopsy
Drug: Phenytoin paste
Placebo Comparator: usual mucoadhesive paste
this group receives the usual mucoadhesive paste without phenytoin after oral biopsy
Drug: Placebo


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients undergone oral biopsy

Exclusion Criteria:

  • systemic disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01680042

Contact: somayeh alirezaei, DDS 09123705943

Iran, Islamic Republic of
Shaheed Beheshti University Recruiting
Tehran, Iran, Islamic Republic of
Contact: somayeh alirezaei, resident    09190129151   
Principal Investigator: somayeh alirezaei, resident         
Shahid Beheshti Medical University Not yet recruiting
Tehran, Iran, Islamic Republic of
Contact: somayeh alirezaei, DDS    09123705943   
Principal Investigator: somayeh alirezaei, DDS         
Sponsors and Collaborators
Shahid Beheshti Medical University
  More Information

No publications provided

Responsible Party: somayeh alirezaei, resident, Shaheed Beheshti Medical University Identifier: NCT01680042     History of Changes
Other Study ID Numbers: Merck-023 
Study First Received: September 3, 2012
Last Updated: October 1, 2012
Health Authority: Iran: Ministry of Health

Keywords provided by Shahid Beheshti Medical University:
inflammatory halo

Additional relevant MeSH terms:
Cardiovascular Agents
Central Nervous System Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Sodium Channel Blockers
Therapeutic Uses
Voltage-Gated Sodium Channel Blockers processed this record on February 09, 2016